Morgan Stanley trimmed its position in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 9.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 262,016 shares of the biopharmaceutical company’s stock after selling 27,327 shares during the period. Morgan Stanley’s holdings in Bellicum Pharmaceuticals were worth $445,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its position in shares of Bellicum Pharmaceuticals by 1,497.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 24,630 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,088 shares in the last quarter. A.R.T. Advisors LLC boosted its position in shares of Bellicum Pharmaceuticals by 256.6% during the 2nd quarter. A.R.T. Advisors LLC now owns 54,339 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 39,100 shares in the last quarter. Weiss Asset Management LP purchased a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter worth $143,000. Algert Global LLC purchased a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter worth $144,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Bellicum Pharmaceuticals during the 2nd quarter worth $233,000. Hedge funds and other institutional investors own 52.87% of the company’s stock.
Several equities research analysts have commented on BLCM shares. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th.
In other news, CEO Richard A. Fair purchased 40,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was acquired at an average price of $1.25 per share, with a total value of $50,000.00. Following the purchase, the chief executive officer now directly owns 66,561 shares of the company’s stock, valued at approximately $83,201.25. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have bought a total of 68,000 shares of company stock valued at $79,640 in the last ninety days. Corporate insiders own 2.64% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.
Further Reading: How Important is Technical Analysis of Stocks
Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals Inc (NASDAQ:BLCM).
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.